Eric Jacobson

2.8k citations
35 papers · 2.1k · h-index 21

Impact in

  • Geriatrics and Gerontology top 0.2%
    • Sirtuins and Resveratrol in Medicine
  • Physiology top 2%
    • Adipose Tissue and Metabolism
    • Calcium signaling and nucleotide metabolism
    • Biochemical effects in animals

Papers in

Co-authors
Ethan Hoffmann (6 shared papers)Jonathan Haddad (6 shared papers)Barbara C. Hegarty (1 shared paper)Karen Brown (1 shared paper)D.P. Berry (1 shared paper)Lynne Howells (1 shared paper)Andreas J. Gescher (1 shared paper)W P Steward (1 shared paper)
Journals
Journal of Clinical Oncology (8 papers)PLoS ONE (4 papers)Inflammatory Bowel Diseases (3 papers)British Journal of Clinical Pharmacology (2 papers)The American Journal of Medicine (2 papers)
Partner nations
United StatesUnited KingdomNetherlands

In The Last Decade

Eric Jacobson

33 papers receiving 2.0k citations

Peers

Eric Jacobson
Comparison fields: 5 of 109
  • Geriatrics and Gerontology 563
  • Physiology 130
  • Aging 38
  • Immunology 362
  • Oncology 303
Replace Paola Signorelli with:
Paola Signorelli Italy
Ji Miao China
Charles‐Henry Cottart France
Gayatri Ramakrishna India
Emeric Limagne France
Neus Carbó Spain
Adam Csordás Austria
Abishek Iyer Australia
John A. Marwick United Kingdom
Shih‐Chang Tsai Taiwan
Eric Jacobson relative to Paola Signorelli Italy Paola Signorelli's profile →
Citations per field
00.5×2×3×4.2×
Paola Signorelli · 1×
Citations per year

Countries citing papers authored by Eric Jacobson

Since Specialization
Citations

This map shows the geographic impact of Eric Jacobson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Jacobson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Jacobson more than expected).

Fields of papers citing papers by Eric Jacobson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Jacobson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Jacobson. The network helps show where Eric Jacobson may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Jacobson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Jacobson Line = papers co-authored together Eric Jacobson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics
Cancer Prevention Research ·Lynne Howells, D.P. Berry, P.J. Elliott, Eric Jacobson, Ethan Hoffmann, Barbara C. Hegarty, Karen Brown, W P Steward, Andreas J. Gescher
2011379
2
Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial
Arthritis & Rheumatism ·Clarissa E. Vergunst, Daniëlle M. Gerlag, Luba Lopatinskaya, Lars Klareskog, Malcolm Smith, Filip Van den Bosch, Huib J. Dinant, Yih Lee, Timothy Wyant, Eric Jacobson, Dominique Baeten, Paul P. Tak
2008185
3
Gamma‐linolenic acid treatment of rheumatoid arthritis. A randomized, placebo‐controlled trial
Arthritis & Rheumatism ·Robert B. Zurier, Ronald G. Rossetti, Eric Jacobson, Deborah M. DeMarco, Nancy Y. Liu, J. Temming, Bernadette White, Michael Laposata
1996161
4
Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
Journal of Clinical Oncology ·Steven O’Day, René González, David H. Lawson, Robert Weber, Laura F. Hutchins, Clay Anderson, Jonathan Haddad, Steven Kong, Anthony T. Williams, Eric Jacobson
2009151
5
Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21
Vaccine ·Douglas C. Waite, Eric Jacobson, Francis A. Ennis, Robert Edelman, Bernadette White, Robert B. Kammer, Christine Anderson, Charlotte R. Kensil
2001119
6
Pharmacokinetics and tolerability of SRT2104, a first‐in‐class small molecule activator of SIRT1, after single and repeated oral administration in man
British Journal of Clinical Pharmacology ·Ethan Hoffmann, J. Wald, Siva Lavu, John G. Roberts, Claire Beaumont, Jon Haddad, Peter J. Elliott, Christoph Westphal, Eric Jacobson
2012113
7
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers
PLoS ONE ·Vincenzo Libri, Andrew Brown, Giulio Gambarota, Jonathan Haddad, Gregory S Shields, Helen Dawes, David J. Pinato, E. Hoffman, Peter Elliot, George P. Vlasuk, Eric Jacobson, Martin R. Wilkins, Paul M. Matthews
2012107
8
A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease
Inflammatory Bowel Diseases ·Robert Burakoff, Charles F. Barish, Dennis Riff, Ronald E. Pruitt, William Y. Chey, Francis A. Farraye, Ira Shafran, Seymour Katz, Charles L. Krone, Martha Vander Vliet, Christopher Stevens, Matthew L. Sherman, Eric Jacobson, Ronald Bleday
200685
9
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
PLoS ONE ·James G. Krueger, Mayte Suárez‐Fariñas, Inna Cueto, Artemis Khacherian, Robert Matheson, Lawrence Charles Parish, Craig L. Leonardi, Denise Shortino, Akanksha Gupta, Jonathan Haddad, George P. Vlasuk, Eric Jacobson
201585
10
Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers
Journal of the American Heart Association ·Sowmya Venkatasubramanian, Radzi M Noh, Shruti Daga, Jeremy P. Langrish, Nikhil Joshi, Nicholas L. Mills, Ethan Hoffmann, Eric Jacobson, George P. Vlasuk, Brian Waterhouse, Ninian N. Lang, David E. Newby
201383
11
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease
Inflammatory Bowel Diseases ·Bruce E. Sands, Eric Jacobson, Thomas Sylwestrowicz, Ziad Younes, Gerald W. Dryden, Richard N. Fedorak, Susan Greenbloom
200982
12
A phase II, randomized, placebo‐controlled, double‐blind, multi‐dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes
British Journal of Clinical Pharmacology ·A Baksi, O. V. Kraydashenko, Alsu Zalevkaya, Roman Stets, Peter J. Elliott, Jonathan Haddad, Ethan Hoffmann, George P. Vlasuk, Eric Jacobson
201472
13
Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis
Arthritis & Rheumatism ·Sarah Krausz, Maria J H Boumans, Daniëlle M. Gerlag, Joelle Lufkin, Arno W. R. van Kuijk, Alian Bakker, Maarten P. Boer, Beatrijs M. Lodde, Kris A. Reedquist, Eric Jacobson, Michael O’Meara, Paul P. Tak
201164
14
The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans*
Critical Care Medicine ·Anne Jan van der Meer, Brendon P. Scicluna, Perry D. Moerland, Jiang Lin, Eric Jacobson, George P. Vlasuk, Tom van der Poll
201557
15
Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis
PLoS ONE ·Yumiko Wada, Irma Cardinale, Artemis Khatcherian, John Man Tak Chu, Aaron B. Kantor, Alice B. Gottlieb, Noriaki Tatsuta, Eric Jacobson, James Barsoum, James G. Krueger
201256
16
Development and Implementation of an Objective Structured Teaching Exercise (OSTE) to Evaluate Improvement in Feedback Skills Following a Faculty Development Workshop
Teaching and Learning in Medicine ·Sarah Stone, Kathleen M. Mazor, Sarah Devaney-O'Neil, Susan Starr, Warren J. Ferguson, Scott Wellman, Eric Jacobson, David Hatem, Mark Quirk
200356
17
Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis
Inflammatory Bowel Diseases ·Bruce E. Sands, Shashidhar Joshi, Jonathan Haddad, Johannes Freudenberg, Deepa Elizabeth Oommen, Ethan Hoffmann, Stewart W. McCallum, Eric Jacobson
201538
18
Evaluation of negative pressure wound therapy to closed laparotomy incisions in acute care surgery
The American Journal of Surgery ·Elleson Schurtz, Jerome A. Differding, Eric Jacobson, Christopher J. Maki, Mentor Ahmeti
201731
19
Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus
Open Heart ·Sowmya Venkatasubramanian, Radzi M Noh, Shruti Daga, Jeremy P. Langrish, Nicholas L. Mills, Brian Waterhouse, Ethan Hoffmann, Eric Jacobson, Ninian N. Lang, Brian M. Frier, David E. Newby
201629
20
Safety and efficacy of intravenous quinidine
The American Journal of Medicine ·Charles D. Swerdlow, Jeanette O. Yu, Eric Jacobson, S. M. Mann, Roger A. Winkle, Jerry C. Griffin, David L. Ross, Jay W. Mason
198324

About Eric Jacobson

Eric Jacobson is a scholar working on Geriatrics and Gerontology, Molecular Biology, Oncology, Organic Chemistry and Cardiology and Cardiovascular Medicine, having authored 35 papers that have together received 2.1k indexed citations. Recurring topics across this work include Sirtuins and Resveratrol in Medicine (9 papers), Click Chemistry and Applications (5 papers), Cancer Treatment and Pharmacology (5 papers), Melanoma and MAPK Pathways (4 papers), Computational Drug Discovery Methods (3 papers), Cardiac electrophysiology and arrhythmias (2 papers), Ion channel regulation and function (2 papers) and Fatty Acid Research and Health (1 paper). The work is most often cited by research in Geriatrics and Gerontology (563 citations), Physiology (130 citations), Aging (38 citations), Immunology (362 citations) and Oncology (303 citations). Eric Jacobson has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Ethan Hoffmann, Jonathan Haddad, Barbara C. Hegarty, Karen Brown, D.P. Berry, Lynne Howells, Andreas J. Gescher, W P Steward, George P. Vlasuk and Bernadette White. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE, Inflammatory Bowel Diseases, British Journal of Clinical Pharmacology and The American Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola SignorelliBreakdown of academic impact, for papers by Ji MiaoBreakdown of academic impact, for papers by Charles‐Henry CottartBreakdown of academic impact, for papers by Gayatri RamakrishnaBreakdown of academic impact, for papers by Emeric LimagneBreakdown of academic impact, for papers by Neus CarbóBreakdown of academic impact, for papers by Adam CsordásBreakdown of academic impact, for papers by Abishek IyerBreakdown of academic impact, for papers by John A. MarwickBreakdown of academic impact, for papers by Shih‐Chang Tsai